Skip to main content
TipRanks
Go Ultimate75% OFF

Cryo-Cell International (ZCY) AI Stock Analysis

0 Followers
DE:ZCY

Cryo-Cell International

(Frankfurt:ZCY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Positive Cash GenerationPositive operating and free cash flow provide internal funding for ongoing operations and reduce immediate reliance on external capital. Cash generation has remained positive from 2024 through TTM, supporting business resilience even while reported net income is negative.
Negative Factors
Negative Stockholders’ EquityDeeply negative equity signals a strained capital structure and reduces financial flexibility, even though total debt is lower than in earlier years. The company may have less capacity to absorb operating setbacks or fund initiatives without rebuilding its balance sheet.

Cryo-Cell International (ZCY) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%30%40%DE:ZCY+2.94%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 33.46M
Dividend Yield
―
Average Volume (3M)
831
Price to Earnings (P/E)
-18.5
Beta (1Y)
0.25
Revenue Growth
-7.46%
EPS Growth
-252.40%
Country
Germany
Employees
74
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical co...

Cryo-Cell International Risk Analysis

Cryo-Cell International disclosed 40 risk factors in its most recent earnings report. Cryo-Cell International reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.We cannot assure you that we will continue to be listed on the NYSE American.Q3, 2026
2.The issuance of additional Common Stock by us in the future would result in dilution to our existing stockholders.Q3, 2026

Cryo-Cell International Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:ZCY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SRTASRTA58Neutral$431.41M-15.69-8.86%―22.73%3.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CCMCCM40Underperform$15.59M-0.035.16%―20.26%69.68%
AIDXAIDX38Underperform$2.53M-0.22-315.65%―――

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%DE:ZCYCCMSRTANIVFBMGLAIDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:ZCY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:ZCYCryo-Cell International 3.500.226.71%
CCMConcord Medical Services3.55-0.45-11.25%
SRTAStrata Critical Medical, Inc.4.560.307.04%
NIVFNewgenivf Group Limited0.03-5664.36-100.00%
BMGLBasel Medical Group Ltd0.38-13.42-97.22%
AIDX20/20 Biolabs, Inc.0.16-23.69-99.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.